Valuation: Crescent Biopharma, Inc.

Market Cap 606M 551M 509M 459M 866M 56.88B 900M 6.11B 2.42B 30.52B 2.27B 2.22B 96.56B P/E 2026 *
-4.16x
P/E 2027 * -4x
Enterprise Value 345M 313M 289M 261M 493M 32.37B 512M 3.48B 1.38B 17.36B 1.29B 1.27B 54.95B EV / Sales 2026 *
79.4x
EV / Sales 2027 * 48.7x
Free-Float
95.24%
Yield 2026 *
-
Yield 2027 * -
1 day-4.59%
1 week-0.30%
Current month+0.15%
1 month+8.17%
3 months-21.24%
6 months-32.40%
Current year+13.83%
1 week 12.95
Extreme 12.95
15.44
1 month 11.82
Extreme 11.82
15.44
Current year 8.72
Extreme 8.72
27.41
1 year 8.72
Extreme 8.72
27.41
3 years 8.72
Extreme 8.72
27.41
5 years 8.72
Extreme 8.72
27.41
10 years 8.72
Extreme 8.72
27.41
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Sell

Chairperson

-3,839 0.0103%
9/18/26 Sell

Chief Executive Officer

-7,837 0.0211%
9/16/26 Sell

Chief Technology Officer

-623 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
-4.59%-0.30%+3.69% - 606M
-0.82%+5.74%+39.64%+143.26% 1,286B
-1.12%+2.29%+44.21%+89.89% 688B
-0.16%+1.11%+26.76%+114.06% 521B
+1.14%+4.87%+43.06%+71.97% 386B
-2.23%-1.55%+55.47%+42.54% 364B
+1.27%+2.01%+30.01%+62.35% 302B
+0.37%+0.75%+3.71%+39.09% 287B
-0.72%+0.41%+37.29%+69.33% 252B
-0.30%+0.41%+34.04%+123.32% 208B
Average -0.47%+2.32%+31.79%+83.98% 429B
Weighted average by Cap. -0.21%+3.26%+36.97%+98.27%

Financials

2026 *2027 *
Net sales 4.34M 3.95M 3.65M 3.29M 6.21M 408M 6.45M 43.8M 17.36M 219M 16.29M 15.95M 692M 3.36M 3.05M 2.82M 2.55M 4.8M 315M 4.99M 33.86M 13.42M 169M 12.59M 12.33M 535M
Net income -124M -113M -104M -94.27M -178M -11.67B -185M -1.25B -497M -6.26B -466M -457M -19.82B -168M -152M -141M -127M -240M -15.74B -249M -1.69B -670M -8.44B -629M -616M -26.72B
Net Debt -261M -237M -219M -198M -373M -24.51B -388M -2.63B -1.04B -13.15B -979M -959M -41.61B -442M -402M -371M -335M -632M -41.51B -657M -4.46B -1.77B -22.27B -1.66B -1.62B -70.47B
Projected Income Statement - Annual - Crescent Biopharma, Inc.
Logo Crescent Biopharma, Inc.
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Employees
80
Date Price Change Volume
26-11-16 $13.50 -4.59% 417,072
26-11-13 $14.15 -1.53% 284,755
26-11-12 $14.37 -2.61% 209,893
26-11-11 $14.76 +6.00% 269,518
26-11-10 $13.92 +1.98% 168,277
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Crescent Biopharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
13.50USD
Average target price
32.33USD
Spread / Average Target
+139.51%
  1. Stock Market
  2. Stocks
  3. CBIO Stock